• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫作为非酒精性脂肪性肝病的基石:氧化应激在疾病进展中的贡献。

Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression.

机构信息

Hepatogastroenterology Division, Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Via S. Pansini 5, 80131 Naples, Italy.

C.U.R.E. (University Center for Liver Disease Research and Treatment), Liver Unit, Department of Medical and Surgical Sciences, University of Foggia, 71121 Foggia, Italy.

出版信息

Int J Mol Sci. 2021 Jan 4;22(1):436. doi: 10.3390/ijms22010436.

DOI:10.3390/ijms22010436
PMID:33406763
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7795122/
Abstract

Non-alcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of metabolic syndrome and has become the major cause of chronic liver disease, especially in western countries. NAFLD encompasses a wide spectrum of hepatic histological alterations, from simple steatosis to steatohepatitis and cirrhosis with a potential development of hepatocellular carcinoma. Non-alcoholic steatohepatitis (NASH) is characterized by lobular inflammation and fibrosis. Several studies reported that insulin resistance, redox unbalance, inflammation, and lipid metabolism dysregulation are involved in NAFLD progression. However, the mechanisms beyond the evolution of simple steatosis to NASH are not clearly understood yet. Recent findings suggest that different oxidized products, such as lipids, cholesterol, aldehydes and other macromolecules could drive the inflammation onset. On the other hand, new evidence indicates innate and adaptive immunity activation as the driving force in establishing liver inflammation and fibrosis. In this review, we discuss how immunity, triggered by oxidative products and promoting in turn oxidative stress in a vicious cycle, fuels NAFLD progression. Furthermore, we explored the emerging importance of immune cell metabolism in determining inflammation, describing the potential application of trained immune discoveries in the NASH pathological context.

摘要

非酒精性脂肪性肝病(NAFLD)被认为是代谢综合征的肝脏表现,已成为慢性肝病的主要病因,尤其在西方国家。NAFLD 涵盖了广泛的肝组织学改变,从单纯性脂肪变性到脂肪性肝炎和肝硬化,并有发展为肝细胞癌的潜在风险。非酒精性脂肪性肝炎(NASH)的特征是小叶炎症和纤维化。多项研究报告称,胰岛素抵抗、氧化还原失衡、炎症和脂质代谢失调参与了 NAFLD 的进展。然而,从单纯性脂肪变性发展为 NASH 的机制尚不清楚。最近的研究结果表明,不同的氧化产物,如脂质、胆固醇、醛类和其他大分子,可能会引发炎症的发生。另一方面,新的证据表明固有免疫和适应性免疫的激活是导致肝脏炎症和纤维化的驱动力。在这篇综述中,我们讨论了免疫如何被氧化产物触发,并在恶性循环中反过来促进氧化应激,从而推动 NAFLD 的进展。此外,我们还探讨了免疫细胞代谢在决定炎症中的新兴重要性,描述了训练有素的免疫发现在 NASH 病理背景下的潜在应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/947b/7795122/3eb0eabfdfe5/ijms-22-00436-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/947b/7795122/020dd21b3460/ijms-22-00436-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/947b/7795122/3eb0eabfdfe5/ijms-22-00436-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/947b/7795122/020dd21b3460/ijms-22-00436-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/947b/7795122/3eb0eabfdfe5/ijms-22-00436-g002.jpg

相似文献

1
Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression.免疫作为非酒精性脂肪性肝病的基石:氧化应激在疾病进展中的贡献。
Int J Mol Sci. 2021 Jan 4;22(1):436. doi: 10.3390/ijms22010436.
2
Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.非酒精性脂肪性肝炎发病机制中的脂质氧化产物。
Free Radic Biol Med. 2017 Oct;111:173-185. doi: 10.1016/j.freeradbiomed.2017.01.023. Epub 2017 Jan 18.
3
Adaptive immunity: an emerging player in the progression of NAFLD.适应性免疫:非酒精性脂肪性肝病进展中的新兴参与者。
Nat Rev Gastroenterol Hepatol. 2020 Feb;17(2):81-92. doi: 10.1038/s41575-019-0210-2. Epub 2019 Oct 11.
4
B2-Lymphocyte responses to oxidative stress-derived antigens contribute to the evolution of nonalcoholic fatty liver disease (NAFLD).B2 淋巴细胞对氧化应激衍生抗原的反应有助于非酒精性脂肪性肝病(NAFLD)的发展。
Free Radic Biol Med. 2018 Aug 20;124:249-259. doi: 10.1016/j.freeradbiomed.2018.06.015. Epub 2018 Jun 18.
5
Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.在小鼠的高脂肪-高胆固醇-高糖饮食模型中,非酒精性脂肪变性进展为脂肪性肝炎和肝纤维化与促进炎症和肝肿瘤的危险信号的累积平行。
J Transl Med. 2015 Jun 16;13:193. doi: 10.1186/s12967-015-0552-7.
6
Redox homeostasis and epigenetics in non-alcoholic fatty liver disease (NAFLD).氧化还原平衡和非酒精性脂肪性肝病 (NAFLD) 的表观遗传学。
Curr Pharm Des. 2013;19(15):2737-46. doi: 10.2174/1381612811319150009.
7
Endoplasmic reticulum stress in innate immune cells - a significant contribution to non-alcoholic fatty liver disease.内质网应激在固有免疫细胞中的作用——对非酒精性脂肪性肝病的重要贡献。
Front Immunol. 2022 Jul 22;13:951406. doi: 10.3389/fimmu.2022.951406. eCollection 2022.
8
The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH).免疫细胞在代谢相关肝炎症和非酒精性脂肪性肝炎(NASH)发展中的作用。
Rev Endocr Metab Disord. 2016 Mar;17(1):29-39. doi: 10.1007/s11154-016-9339-2.
9
Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.非酒精性脂肪性肝病:从非酒精性脂肪性肝病到非酒精性脂肪性肝炎的进展中的基本发病机制。
Transplantation. 2019 Jan;103(1):e1-e13. doi: 10.1097/TP.0000000000002480.
10
Oxidative Stress in NAFLD: Role of Nutrients and Food Contaminants.非酒精性脂肪性肝病中的氧化应激:营养素和食物污染物的作用。
Biomolecules. 2020 Dec 21;10(12):1702. doi: 10.3390/biom10121702.

引用本文的文献

1
From "Traditional" to "Trained" Immunity: Exploring the Novel Frontiers of Immunopathogenesis in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).从“传统”免疫到“训练有素”的免疫:探索代谢功能障碍相关脂肪性肝病(MASLD)进展中免疫发病机制的新前沿
Biomedicines. 2025 Aug 18;13(8):2004. doi: 10.3390/biomedicines13082004.
2
Identification of foam cell like M2 macrophages, AEBP1 biomarkers, and resveratrol as potential therapeutic in MASLD using Ecotyper and WGCNA.使用Ecotyper和加权基因共表达网络分析(WGCNA)鉴定泡沫细胞样M2巨噬细胞、AEBP1生物标志物以及白藜芦醇作为非酒精性脂肪性肝炎(MASLD)潜在治疗方法。
Sci Rep. 2025 Aug 18;15(1):30233. doi: 10.1038/s41598-025-15191-6.
3

本文引用的文献

1
Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease.非酒精性脂肪性肝病肝外表现的评估与管理。
Clin Mol Hepatol. 2021 Apr;27(2):221-235. doi: 10.3350/cmh.2020.0239. Epub 2020 Dec 3.
2
Hepatic Stellate Cells and Hepatocarcinogenesis.肝星状细胞与肝癌发生
Front Cell Dev Biol. 2020 Aug 5;8:709. doi: 10.3389/fcell.2020.00709. eCollection 2020.
3
Lipid Metabolism in Development and Progression of Hepatocellular Carcinoma.脂质代谢在肝细胞癌发生发展中的作用
Exploring the role of xanthine oxidase and aldehyde oxidase in metabolic dysfunction-associated steatotic liver disease (MASLD).
探索黄嘌呤氧化酶和醛氧化酶在代谢功能障碍相关脂肪性肝病(MASLD)中的作用。
J Mol Histol. 2025 Jul 23;56(4):237. doi: 10.1007/s10735-025-10507-2.
4
Trained immunity: A new player in cancer immunotherapy.训练有素的免疫:癌症免疫治疗中的新角色。
Elife. 2025 Jun 18;14:e104920. doi: 10.7554/eLife.104920.
5
The Role of the Gut-Biliary-Liver Axis in Primary Hepatobiliary Liver Cancers: From Molecular Insights to Clinical Applications.肠道-胆管-肝脏轴在原发性肝胆管癌中的作用:从分子洞察到临床应用
J Pers Med. 2025 Mar 24;15(4):124. doi: 10.3390/jpm15040124.
6
Clinical Applications of Artificial Intelligence (AI) in Human Cancer: Is It Time to Update the Diagnostic and Predictive Models in Managing Hepatocellular Carcinoma (HCC)?人工智能(AI)在人类癌症中的临床应用:是时候更新肝细胞癌(HCC)管理中的诊断和预测模型了吗?
Diagnostics (Basel). 2025 Jan 22;15(3):252. doi: 10.3390/diagnostics15030252.
7
FLAME: Training and Validating a Newly Conceived Model Incorporating Alpha-Glutathione-S-Transferase Serum Levels for Predicting Advanced Hepatic Fibrosis and Acute Cardiovascular Events in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).FLAME:训练和验证一个新构建的模型,该模型纳入α-谷胱甘肽-S-转移酶血清水平以预测代谢功能障碍相关脂肪性肝病(MASLD)中的晚期肝纤维化和急性心血管事件。
Int J Mol Sci. 2025 Jan 17;26(2):761. doi: 10.3390/ijms26020761.
8
The gender and age perspectives of allostatic load.应激负荷的性别与年龄视角
Front Med (Lausanne). 2024 Dec 17;11:1502940. doi: 10.3389/fmed.2024.1502940. eCollection 2024.
9
In Vitro Nonalcoholic Fatty Liver Disease Model Elucidating the Effect of Immune Environment on Disease Progression and Alleviation.体外非酒精性脂肪性肝病模型:阐明免疫环境对疾病进展和缓解的影响
ACS Omega. 2024 May 27;9(23):25094-25105. doi: 10.1021/acsomega.4c02433. eCollection 2024 Jun 11.
10
The influence of acute lifestyle changes on NAFLD evolution in a multicentre cohort: a matter of body composition.多中心队列研究中急性生活方式改变对非酒精性脂肪性肝病演变的影响:与身体成分有关。
Nutr Diabetes. 2024 May 27;14(1):33. doi: 10.1038/s41387-024-00294-2.
Cancers (Basel). 2020 May 31;12(6):1419. doi: 10.3390/cancers12061419.
4
Dimethyl fumarate ameliorates hepatic inflammation in alcohol related liver disease.富马酸二甲酯可改善酒精性肝病中的肝脏炎症。
Liver Int. 2020 Jul;40(7):1610-1619. doi: 10.1111/liv.14483. Epub 2020 May 6.
5
Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism.肥胖与非酒精性脂肪性肝病中的巨噬细胞:与代谢的相互作用
JHEP Rep. 2019 Feb 23;1(1):30-43. doi: 10.1016/j.jhepr.2019.02.004. eCollection 2019 May.
6
Liver macrophages inhibit the endogenous antioxidant response in obesity-associated insulin resistance.肝脏巨噬细胞抑制肥胖相关胰岛素抵抗中的内源性抗氧化反应。
Sci Transl Med. 2020 Feb 26;12(532). doi: 10.1126/scitranslmed.aaw9709.
7
MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.MAFLD:代谢相关脂肪性肝病的共识驱动命名建议。
Gastroenterology. 2020 May;158(7):1999-2014.e1. doi: 10.1053/j.gastro.2019.11.312. Epub 2020 Feb 8.
8
Itaconate modulates tricarboxylic acid and redox metabolism to mitigate reperfusion injury.衣康酸盐调节三羧酸和氧化还原代谢以减轻再灌注损伤。
Mol Metab. 2020 Feb;32:122-135. doi: 10.1016/j.molmet.2019.11.019. Epub 2019 Dec 13.
9
Immune-Responsive Gene 1/Itaconate Activates Nuclear Factor Erythroid 2-Related Factor 2 in Hepatocytes to Protect Against Liver Ischemia-Reperfusion Injury.免疫应答基因 1/衣康酸激活肝细胞核因子红细胞 2 相关因子 2 以保护肝脏免受缺血再灌注损伤。
Hepatology. 2020 Oct;72(4):1394-1411. doi: 10.1002/hep.31147. Epub 2020 Oct 12.
10
The role of Toll-like receptor 10 in modulation of trained immunity.Toll 样受体 10 在训练免疫调节中的作用。
Immunology. 2020 Mar;159(3):289-297. doi: 10.1111/imm.13145. Epub 2019 Nov 26.